We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Automated Soluble Fibrin Assays Evaluated

By LabMedica International staff writers
Posted on 26 Dec 2013
Print article
Image: Micrograph of acute thrombotic microangiopathy disseminated intravascular coagulation (Photo courtesy of Nephron).
Image: Micrograph of acute thrombotic microangiopathy disseminated intravascular coagulation (Photo courtesy of Nephron).
The soluble fibrin monomer (sFM) assay has the potential to be used both as an aid in the diagnosis of disseminated intravascular coagulation (DIC) and as a thrombotic marker.

The sFM test differs from the D-dimer (Ddi) assay in that it detects a much earlier produced fragment produced only by thrombin action on fibrinogen, whereas Ddi is a much later produced fragment formed by plasmin cleavage of cross-linked fibrin.

Scientists at the Karolinska University Hospital (Solna, Sweden) compared two commercially available automated sFM assays in the routine hospital setting using samples obtained from the general hospital ward and the emergency room. The results obtained with the two automated assays were compared with each other and with the results obtained using the routine semiquantitative hemagglutination assay.

The study showed that both automated assays, the LIAtest sFM assay (Diagnostica Stago; Genevilliers, France) and the LPIA-Iatro SF assay (Mitsubishi Kagaku Bio-Clinical Laboratories; Tokyo, Japan) were analogous with each other. No patient sample previously classified as positive would be missed, but with the higher sensitivity in the automated tests, more samples are positive.

The authors concluded that both automated tests are suitable for routine laboratory use. Both assays had the advantage over the hemagglutination assay in that previously frozen samples could be used, and the assays are easier and quicker to perform. The LIA sFM Stago has slightly better sensitivity but has a tendency to lower specificity than the Iatro SF test. The study was published in the December 2103 issue of the International Journal of Laboratory Hematology.

Related Links:

Karolinska University Hospital
Diagnostica Stago 
Mitsubishi Kagaku Bio-Clinical Laboratories


Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Community-Acquired Pneumonia Test
RIDA UNITY CAP Bac
New
Binocular Laboratory LED Illuminated Microscope
HumaScope Classic LED

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.